Citigroup: Downgrade Q TECH (01478) target price to HK$9, downgraded rating to "Neutral"
The company expects to have a capital expenditure of 1 billion RMB this year, mainly for the automotive or IoT business, with some also allocated for high-end smartphones.
Citigroup released a research report stating that Q TECH (01478) met its earlier forecast for last year's performance. The bank lowered the company's earnings per share forecast for 2026 to 2027 by 39% and 33% respectively to reflect the headwinds facing the smartphone business, partially offset by the non-phone business. The target price was lowered from HK$12 to HK$9, with the rating downgraded from "buy" to "neutral".
The bank mentioned that Q TECH's management guided that the shipment volume of mobile camera modules (HCM) increased by over 5% year-on-year, while the shipment volume of other camera modules (CCM) increased by over 50%. The shipment volume of optical image stabilization (OIS) may decline, but the high-end product mix of CCM will continue to rise. In addition, the company expects capital spending of 1 billion yuan this year, mainly for automotive or IoT businesses, with a portion allocated to high-end smartphones.
Related Articles

Beijing Wandong Medical Technology (600055.SH): "Magnetic Resonance Imaging System" has obtained a medical device registration certificate.

HK Stock Market Move | CHINA RES MIXC (01209) up nearly 5% in midday trading, company expected to announce annual performance at the end of the month, institutions predict dividend policy will continue.

Sinotherapeutics Inc. (688247.SH): Xuantai Tomato Red Grape Seed Extract Tablets have obtained the registration certificate for domestic health food.
Beijing Wandong Medical Technology (600055.SH): "Magnetic Resonance Imaging System" has obtained a medical device registration certificate.

HK Stock Market Move | CHINA RES MIXC (01209) up nearly 5% in midday trading, company expected to announce annual performance at the end of the month, institutions predict dividend policy will continue.

Sinotherapeutics Inc. (688247.SH): Xuantai Tomato Red Grape Seed Extract Tablets have obtained the registration certificate for domestic health food.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


